JW Pharmaceutical is accelerating the development of innovative first-in-class drugs. Recently, the company's STAT3-targeted anticancer drug candidate entered Phase I clinical trials. In addition to targeted anticancer drugs, the company also owns first-in-class drug candidates in the fields of atopic dermatitis, hair loss, and blood cancer.

JW Pharmaceutical's competitive edge in drug development is its R&D platform. JW Pharmaceutical is developing innovative new drugs by utilizing its own platforms JWELRY (JW Excellent LibraRY) and CLOVER (C&C researchLaboratoriesOmics serVER) and 3D cancer organoids secured through open innovation, and artificial intelligence (AI).

3 3 candidates

Son, Hyung-Min(shm@dailypharm.com)